市場調査レポート

商品コード

プロテオミクス：各種技術と世界の市場

Proteomics: Technologies and Global Markets

出版日: 2022年12月05日 | 発行: BCC Research

| ページ情報: 英文 384 Pages | 納期: 即納可能

価格

PDF (Single User License)

USD 5,500 865,480円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は、機能制限があるわけではありませんが、1回までとされます。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 Users)

USD 6,600 1,038,576円

レポートPDFを同一国内の5名迄にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は計5回までとされます。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Site License)

USD 7,920 1,246,291円

レポートPDFを同一事業所に所属される方にて人数に制限なく共有ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。印刷機能に回数制限はありませんが、印刷したもののご利用はPDFのご利用者と同一範囲内です。

PDF (Enterprise License)

USD 9,504 1,495,549円

レポートPDFを同一企業の全ての事業所（資本100%子会社含む）にて人数に制限なく共有ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。印刷機能に回数制限はなく、同一企業内にて配布ご利用可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.36円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のプロテオミクスの市場規模は、2022年の271億米ドルから、2027年には551億米ドルに成長し、2022年から2027年にかけてのCAGRは15.3％と予測されています。

創薬・開発の部門は、2022年の140億米ドルから、2027年には261億米ドルに成長し、2022年から2027年にかけてのCAGRは13.2％と予測されています。また、診断の部門は、2022年の74億米ドルから、2027年には174億米ドルに成長し、CAGRは18.5%と予測されています。

当レポートでは、世界のプロテオミクスの技術および市場を調査し、関連技術と発展の動向、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合環境、主要企業のプロファイルなどをまとめています。

MSベースプロテオミクス技術
- サンプル調製アッセイ
- タグ付け/アフィニティ法
- バイオマーカー同定のためのプロテオミクスの有用性
- MS機器および消耗品
バイオチップベースプロテオミクス技術
- マルチプレックスプロテオミクスシステム
- プロテオゲノミクス
- プロテオミクス技術の最近の進歩

第6章創薬・開発におけるプロテオミクスの応用

ターゲット発見
リード識別
リード最適化
前臨床研究

第7章プロテオミクスの科学的イニシアチブ

第8章プロテオミクスの臨床用途

癌への応用
- 概要
- 膀胱癌
- 乳癌
- 大腸癌
- 胃癌
- 腎癌
- 肺癌
- リンパ腫
- 卵巣癌
- 汎癌
- 前立腺癌
- 甲状腺癌
- その他の癌
感染症
糖尿病
神経学的障害
- アルツハイマー病
- 統合失調症
免疫疾患
- HLAタイピング
- 自己免疫疾患
循環器疾患
子癇前症

第9章プロテオミクス産業

産業買収
産業の戦略的提携
質量分析産業
クロマトグラフィー産業
プロテオミクスベースの創薬および開発産業
プロテオミクスバイオチップ産業
- ペプチドマイクロアレイ産業
- 高密度タンパク質アレイ産業
抗体マイクロアレイ産業
中国のバイオチップ産業
Lab-on-a-Chipプロテオミクス産業
化学プロテオミクス産業
抗体試薬産業
マルチプレックスタンパク質診断産業
乾燥血液スポッティングプロテオミクス産業
単一細胞プロテオミクス産業

第10章プロテオミクス市場

プロテオミクス産業の成長の原動力
世界のプロテオミクス市場
市場概要
調査市場
創薬・開発市場
プロテオミクス診断市場
質量分析ベースプロテオミクス市場
バイオチップベースプロテオミクス市場

第11章プロテオミクス市場：地域別

北米
欧州
アジア太平洋
その他の地域

第12章プロテオミクス特許

米国のプロテオミクス特許
タンパク質アレイ特許

第13章競合情勢

ゲノミクスおよびプロテオミクスのツール/技術
- シーケンシング技術
- PCR技術
- 核酸精製・分離
- 核酸分離技術

第14章企業プロファイル

ABCODIA LTD.
ACTIVX BIOSCIENCES INC.
ADVANCED PROTEOME THERAPEUTICS INC.
AGILENT TECHNOLOGIES INC.
APPLIED PROTEOMICS
ARRAYIT CORP.
ASTUTE MEDICAL INC.
AVACTA LIFE SCIENCES LTD.
AYOXXA BIOSYSTEMS GMBH
BECTON, DICKINSON AND CO.
BIOCARTIS NV
BIODESIX INC.
BIOGNOSYS AG
BIOMERIEUX SA
BIO-RAD LABORATORIES INC.
BIO-TECHNE INC.
BRUKER CORP.
CAMBRIDGE PROTEIN ARRAYS LTD.
CHARLES RIVER LABORATORIES INTERNATIONAL INC.
CRYSTALGENOMICS INC.
DANAHER CORP.
EPICYPHER INC.
EVOTEC AG
GENERAL ELECTRIC CO.
GLAXOSMITHKLINE PLC
GL SCIENCES INC.
ILLUMINA INC.
IMMUNOVIA AB
IMTAKT CORP.
INTEGRATED DIAGNOSTICS HOLDING
INDI MOLECULAR
LABCYTE INC.
LIMINAL BIOSCIENCES INC.
MERCK & CO. INC.
MERCK KGAA
MRM PROTEOMICS INC.
MYCARTIS
MYRIAD GENETICS INC.
NEWOMICS INC.
NIRMIDAS BIOTECH INC.
OLINK BIOSCIENCE
OPKO HEALTH INC.
PERKINELMER INC.
PERSONALIZED CANCER THERAPY INC.
PFIZER INC.
PHENOMENEX INC.
PRESSURE BIOSCIENCES INC.
PROTAGEN AG
PROTEA BIOSCIENCES INC.
PROTEOCYTE DIAGNOSTICS INC.
PROTEOGENIX
PROTEOME SCIENCES PLC
PROTEOMICS INTERNATIONAL PTY LTD.
PYC THERAPEUTICS.（FORMERLY PHYLOGICA LTD.）
QIAGEN N.V.
QUANSYS BIOSCIENCES
QUANTERIX INC.
QUEST DIAGNOSTICS INC.
REPLIGEN CORP.
ROCHE（F. HOFFMANN-LA ROCHE LTD.）
SAMDI TECH INC.
SANOFI
SERA PROGNOSTICS
SHIMADZU CORP.
SHISEIDO COMPANY LTD.
SHOWA DENKO KK
SINGULEX INC.
SISCAPA ASSAY TECHNOLOGIES INC.
SOMALOGIC INC.
SPOTON CLINICAL DIAGNOSTICS LTD.
SQI DIAGNOSTICS
STANDARD BIOTOOLS INC.（FORMERLY FLUIDIGM）
SYNAGEVA BIOPHARMA（ACQUIRED BY ALEXION PHARMACEUTICALS INC.）
T2 BIOSYSTEMS
THERMO FISHER SCIENTIFIC INC.
THORNE DIAGNOSTICS INC.
TOSOH CORP.
TRAJAN SCIENTIFIC AND MEDICAL
UNIVERSAL BIOSENSORS LTD.
VG LIFE SCIENCES INC.
WATERS CORP.
XENCOR INC.
YMC CO. LTD.

図表

List of Tables

Summary Table A : Global Proteomics Market, by End-User Industry, Through 2027
Summary Table B : Global Proteomics Market, by Platform, Through 2027
Table 1 : Global Array Versus Lab-on-a-Chip (LOC) Biochips
Table 2 : Scope of Report
Table 3 : Global Proteomics Market, by Platform, Through 2027
Table 4 : Global Biochips Market, by Type, Through 2027
Table 5 : Driving Forces in the Growth of the Proteomics Industry
Table 6 : Biochip Industry Comparisons
Table 7 : Mass Spectrometry Generalized Workflow Schematic
Table 8 : Mass Spectrometer Platforms
Table 9 : Biochip-Based Proteomics Technologies
Table 10 : Planar-Based Versus Bead-Based Arrays
Table 11 : Advantages of Multiplexing for Diagnostics
Table 12 : Technical Advances in Proteomics
Table 13 : Proteomic Applications in Drug Discovery and Development
Table 14 : Large-Scale Proteomics Initiatives
Table 15 : Some Cancer Markers Used in Diagnosis and Treatment
Table 16 : Strategies for Overcoming High-Abundance Proteins in Clinical Samples
Table 17 : Status of Next-Generation Diagnostic Tests for Bladder Cancer
Table 18 : Number of Annual Breast Cancer Treatment Decisions in the U.S, by Cancer Classification
Table 19 : Breast Cancer MDx Technology Platforms
Table 20 : Status of Next-Generation Tests for Breast Cancer
Table 21 : Status of Next-Generation Diagnostic Tests for Gastric/Stomach Cancer
Table 22 : Status of Next-Generation Diagnostic Tests for Kidney Cancer
Table 23 : Status of Next-Generation Diagnostic Tests for Lung Cancer
Table 24 : Status of Next-Generation Diagnostic Tests for Lymphomas
Table 25 : Early Screening Tests for Ovarian Cancer
Table 26 : Status of Next-Generation Diagnostics Tests for Ovarian Cancer
Table 27 : Status of Next-Generation Diagnostics Tests for Pan-Cancer
Table 28 : Status of Next-Generation Diagnostics Tests for Prostate Cancer
Table 29 : Status of Next-Generation Diagnostics Tests for Thyroid Cancer
Table 30 : Alzheimer's Disease Diagnostic Approaches
Table 31 : Multiplex Autoimmune Testing Market
Table 32 : Preeclampsia Diagnostic Tests
Table 33 : Proteomics Industry Acquisitions, 2017-2022
Table 34 : Strategic Alliances in the Proteomics Industry
Table 35 : Mass Spectrometry Industry: Porter's Five Forces Analysis
Table 36 : First-Tier Mass Spectrometry Companies
Table 37 : Second-Tier Mass Spectrometry Companies
Table 38 : Leading Manufacturers of High-Performance Liquid Chromatography Columns
Table 39 : Leading Manufacturers of High-Performance Liquid Chromatography Columns in Japan
Table 40 : Proteomics-Based Drug Discovery Industry
Table 41 : Key Peptide Microarray Companies
Table 42 : Leading High-Density Protein Array Companies
Table 43 : Key Antibody Microarray Companies
Table 44 : Leading Companies in China's Biochip Industry
Table 45 : Lab-on-a-Chip Competitor Landscape
Table 46 : Antibody Reagent Market Share, by Company, 2021
Table 47 : Multiplex Protein In Vitro Diagnostics Companies
Table 48 : Dried Blood Spot Proteomics Industry
Table 49 : Single Cell Proteomics Industry
Table 50 : Factors Driving the Growth of the Proteomics Industry
Table 51 : Global Proteomic Market, by End-User Industry, Through 2027
Table 52 : Global Proteomics Research Market, by Platform, Through 2027
Table 53 : Global Proteomics Research Market, by Biochip Platform, Through 2027
Table 54 : Global Proteomics Drug Discovery and Development Market, by Platform, Through 2027
Table 55 : Global Proteomics Biochip Drug Discovery and Development Market, by Biochip Platform, Through 2027
Table 56 : Global Proteomics Diagnostic Market, by Platform, Through 2027
Table 57 : Global Proteomics Diagnostic Market, by Biochip Type, Through 2027
Table 58 : Global Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 59 : Status of Proteomics-Based Diagnostics for Diabetes, Neurological, Autoimmune, Infectious Disease, HLA Typing, and Cardiovascular Disease Applications
Table 60 : Sepsis Diagnostics Industry
Table 61 : Global Proteomics Cancer Diagnostic Market, by Indication, Through 2027
Table 62 : Global Mass Spectrometry Market, by Product Type, Through 2027
Table 63 : Global Mass Spectrometry Market, by End-User Industry, Through 2027
Table 64 : MRM-MS versus MALDI MS in Clinical Applications
Table 65 : Status of MS Clinical Test Platforms
Table 66 : Phosphoproteomics Platforms for Cancer Applications
Table 67 : Global Proteomics Biochip Market, by Type, Through 2027
Table 68 : Global Proteomics Arrays Market, by Type, Through 2027
Table 69 : Global Proteomics Market, by End-User Industry, Through 2027
Table 70 : Global Proteomics Drug Discovery and Development Market, by Platform, Through 2027
Table 71 : Global Proteomics Lab-on-a-Chip Market, by End-User Industry, Through 2027
Table 72 : Global Proteomics Market, by Region, Through 2027
Table 73 : Global Proteomic Diagnostic Market, by Region, Through 2027
Table 74 : North American Proteomics Market by Country, Through 2027
Table 75 : North American Proteomics Market, by Platform, Through 2027
Table 76 : North American Proteomics Market, by Biochips Platform, Through 2027
Table 77 : North American Proteomics Market, by End User, Through 2027
Table 78 : North American Drug Discovery and Development Market, by Platform, Through 2027
Table 79 : North American Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 80 : North American Proteomics Research Market, by Platform, Through 2027
Table 81 : U.S. Proteomics Market, by Platform, Through 2027
Table 82 : U.S. Proteomics Market, by Biochips Platform, Through 2027
Table 83 : U.S. Proteomics Market, by End User, Through 2027
Table 84 : U.S. Drug Discovery and Development Market, by Platform, Through 2027
Table 85 : U.S. Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 86 : U.S. Proteomics Research Market, by Platform, Through 2027
Table 87 : Canadian Proteomics Market, by Platform, Through 2027
Table 88 : Canadian Proteomics Market, by Biochips Platform, Through 2027
Table 89 : Canadian Proteomics Market, by End User, Through 2027
Table 90 : Canadian Drug Discovery and Development Market, by Platform, Through 2027
Table 91 : Canadian Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 92 : Canadian Proteomics Research Market, by Platform, Through 2027
Table 93 : European Proteomics Market, by Country, Through 2027
Table 94 : European Proteomics Market, by Platform, Through 2027
Table 95 : European Proteomics Market, by Biochips Platform, Through 2027
Table 96 : European Proteomics Market, by End User, Through 2027
Table 97 : European Drug Discovery and Development Market, by Platform, Through 2027
Table 98 : European Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 99 : European Proteomics Research Market, by Platform, Through 2027
Table 100 : U.K. Proteomics Market, by Platform, Through 2027
Table 101 : U.K. Proteomics Market, by Biochips Platform, Through 2027
Table 102 : U.K. Proteomics Market, by End User, Through 2027
Table 103 : U.K. Drug Discovery and Development Market, by Platform, Through 2027
Table 104 : U.K. Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 105 : U.K. Proteomics Research Market, by Platform, Through 2027
Table 106 : German Proteomics Market, by Platform, Through 2027
Table 107 : German Proteomics Market, by Biochips Platform, Through 2027
Table 108 : German Proteomics Market, by End User, Through 2027
Table 109 : German Drug Discovery and Development Market, by Platform, Through 2027
Table 110 : German Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 111 : German Proteomics Research Market, by Platform, Through 2027
Table 112 : French Proteomics Market, by Platform, Through 2027
Table 113 : French Proteomics Market, by Biochips Platform, Through 2027
Table 114 : French Proteomics Market, by End User, Through 2027
Table 115 : French Drug Discovery and Development Market, by Platform, Through 2027
Table 116 : French Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 117 : French Proteomics Research Market, by Platform, Through 2027
Table 118 : Italian Proteomics Market, by Platform, Through 2027
Table 119 : Italian Proteomics Market, by Biochips Platform, Through 2027
Table 120 : Italian Proteomics Market, by End User, Through 2027
Table 121 : Italian Drug Discovery and Development Market, by Platform, Through 2027
Table 122 : Italian Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 123 : Italian Proteomics Research Market, by Platform, Through 2027
Table 124 : Spanish Proteomics Market, by Platform, Through 2027
Table 125 : Spanish Proteomics Market, by Biochips Platform, Through 2027
Table 126 : Spanish Proteomics Market, by End User, Through 2027
Table 127 : Spanish Drug Discovery and Development Market, by Platform, Through 2027
Table 128 : Spanish Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 129 : Spanish Proteomics Research Market, by Platform, Through 2027
Table 130 : Rest of European Proteomics Market, by Platform, Through 2027
Table 131 : Rest of European Proteomics Market, by Biochips Platform, Through 2027
Table 132 : Rest of European Proteomics Market, by End User, Through 2027
Table 133 : Rest of European Drug Discovery and Development Market, by Platform, Through 2027
Table 134 : Rest of European Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 135 : Rest of European Proteomics Research Market, by Platform, Through 2027
Table 136 : Asia-Pacific Proteomics Market, by Country, Through 2027
Table 137 : Asia-Pacific Proteomics Market, by Platform, Through 2027
Table 138 : Asia-Pacific Proteomics Market, by Biochips Platform, Through 2027
Table 139 : Asia-Pacific Proteomics Market, by End User, Through 2027
Table 140 : Asia-Pacific Drug Discovery and Development Market, by Platform, Through 2027
Table 141 : Asia-Pacific Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 142 : Asia-Pacific Proteomics Research Market, by Platform, Through 2027
Table 143 : Chinese Proteomics Market, by Platform, Through 2027
Table 144 : Chinese Proteomics Market, by Biochips Platform, Through 2027
Table 145 : Chinese Proteomics Market, by End User, Through 2027
Table 146 : Chinese Drug Discovery and Development Market, by Platform, Through 2027
Table 147 : Chinese Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 148 : Chinese Proteomics Research Market, by Platform, Through 2027
Table 149 : Japanese Proteomics Market, by Platform, Through 2027
Table 150 : Japanese Proteomics Market, by Biochips Platform, Through 2027
Table 151 : Japanese Proteomics Market, by End User, Through 2027
Table 152 : Japanese Drug Discovery and Development Market, by Platform, Through 2027
Table 153 : Japanese Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 154 : Japanese Proteomics Research Market, by Platform, Through 2027
Table 155 : Indian Proteomics Market, by Platform, Through 2027
Table 156 : Indian Proteomics Market, by Biochips Platform, Through 2027
Table 157 : Indian Proteomics Market, by End User, Through 2027
Table 158 : Indian Drug Discovery and Development Market, by Platform, Through 2027
Table 159 : Indian Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 160 : Indian Proteomics Research Market, by Platform, Through 2027
Table 161 : South Korean Proteomics Market, by Platform, Through 2027
Table 162 : South Korean Proteomics Market, by Biochips Platform, Through 2027
Table 163 : South Korean Proteomics Market, by End User, Through 2027
Table 164 : South Korean Drug Discovery and Development Market, by Platform, Through 2027
Table 165 : South Korean Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 166 : South Korean Proteomics Research Market, by Platform, Through 2027
Table 167 : Australian Proteomics Market, by Platform, Through 2027
Table 168 : Australian Proteomics Market, by Biochips Platform, Through 2027
Table 169 : Australian Proteomics Market, by End User, Through 2027
Table 170 : Australian Drug Discovery and Development Market, by Platform, Through 2027
Table 171 : Australian Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 172 : Australian Proteomics Research Market, by Platform, Through 2027
Table 173 : Rest of Asia-Pacific Proteomics Market, by Platform, Through 2027
Table 174 : Rest of Asia-Pacific Proteomics Market, by Biochips Platform, Through 2027
Table 175 : Rest of Asia-Pacific Proteomics Market, by End User, Through 2027
Table 176 : Rest of Asia-Pacific Drug Discovery and Development Market, by Platform, Through 2027
Table 177 : Rest of Asia-Pacific Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 178 : Rest of Asia-Pacific Proteomics Research Market, by Platform, Through 2027
Table 179 : Rest of the World Proteomics Market, by Platform, Through 2027
Table 180 : Rest of the World Proteomics Market, by Biochips Platform, Through 2027
Table 181 : Rest of the World Proteomics Market, by End User, Through 2027
Table 182 : Rest of the World Drug Discovery and Development Market, by Platform, Through 2027
Table 183 : Rest of the World Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 184 : Rest of the World Proteomics Research Market, by Platform, Through 2027
Table 185 : U.S. Proteomics Patents, 2017-2022
Table 186 : Europe: Proteomics Patents, 2017-2022
Table 187 : Japan: Proteomics Patents, 2017-2022
Table 188 : Array-related Proteomics Patents, by Region, 2017-2022
Table 189 : LOC-Related Proteomics Patents, by Region, 2017-2022
Table 190 : Mass Spectrometry-Related Proteomics Patents, by Region, 2017-2022
Table 191 : Major Mergers, Acquisitions, Collaborations, Partnership, Spin-Offs and Agreements
Table 192 : FDA Clearances, Patents and Approvals, 2017-2022
Table 193 : New Product Launches, 2017-2022
Table 194 : Key Products of Sequencing and Next-Generation Sequencing Tools and Reagents and Their Manufacturers in Asia-Pacific
Table 195 : Top Manufacturers of PCR Technologies for Emerging Markets of Asia-Pacific for Research and Clinical Diagnostics
Table 196 : Key Products of PCR Tools and Reagents and Their Manufacturers in Asia-Pacific
Table 197 : Top Manufacturers of Nucleic Acid Purification and Extraction Technologies for Emerging Markets of Asia-Pacific for Research and Clinical Diagnostics
Table 198 : Key Products of Nucleic Acid Purification and Extraction Tools and Reagents and Their Manufacturers in Asia-Pacific
Table 199 : Top Manufacturers of Nucleic Acid Separation Technologies for Emerging Markets of Asia-Pacific for Research and Clinical Diagnostics
Table 200 : Nucleic Acid Separation Technologies: Key Manufacturers' Product Portfolio
Table 201 : Agilent: Laboratory Automation Systems and Processes Portfolio
Table 202 : Agilent Technologies Inc.: Developments
Table 203 : BD: Laboratory Automation Systems and Processes Portfolio
Table 204 : BioMerieux: FDA Bacteriology Products Approved in 2020
Table 205 : BioMerieux: Key Developments, 2021
Table 206 : Bio-Rad: Key Developments, 2021
Table 207 : Danaher Corp.: Key Developments
Table 208 : GE Healthcare: Product Portfolio
Table 209 : General Electric: Financials, 2019
Table 210 : GE Healthcare: Product Portfolio
Table 211 : GE Healthcare: Recent Developments
Table 212 : GlaxoSmithKline PLC: Product Segment
Table 213 : GlaxoSmithKline PLC: Key Financials, 2021
Table 214 : GlaxoSmithKline PLC: Vaccines Offered
Table 215 : GlaxoSmithKline PLC: Flu Vaccines Sales
Table 216 : GlaxoSmithKline PLC: Recent Developments
Table 217 : Illumina Inc.: Revenues and R&D Expenditures
Table 218 : Illumina Inc.: Key Developments
Table 219 : PerkinElmer Inc.: Revenues and R&D Expenditures
Table 220 : PerkinElmer Inc.: Laboratory Automation Systems and Processes Portfolio
Table 221 : PerkinElmer Inc.: Selected Recent Developments
Table 222 : Pressure BioSciences Inc.: Revenues and R&D Expenditures
Table 223 : Pressure BioSciences Inc.: Key Developments
Table 224 : Qiagen GmbH: Laboratory Automation Systems and Processes Portfolio
Table 225 : Qiagen GmbH: Developments
Table 226 : Roche: Business Segment
Table 227 : Roche: Financials, 2021
Table 228 : Roche: Financial Performance, 2018-2020
Table 229 : Roche: Product Portfolio
Table 230 : Roche: Diagnostics Patient Monitoring Product Portfolio
Table 231 : Roche: Oncology Pharmaceutical Product Portfolio
Table 232 : Roche: Oncology Pharmaceutical Revenue, 2018-2020
Table 233 : Roche: Recent Developments
Table 234 : Sanofi: Business Segment
Table 235 : Sanofi: Financial Performance, 2021
Table 236 : Sanofi-Aventis: Oncology Pharmaceuticals Product Portfolio
Table 237 : Sanofi-Aventis: Oncology Pharmaceuticals Revenue, 2018-2020
Table 238 : Somalogic: Proteomics Methods
Table 239 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 240 : Thermo Fisher Scientific Inc.: Developments
Table 241 : Universal Biosensors Diagnostic Pipeline
Table 242 : Waters Corp.: Revenues and R&D Expenditures
Table 243 : Waters Corp.: Laboratory Automation Systems and Processes Portfolio
Table 244 : Waters Corp.: Key Developments

List of Figures

Summary Figure A : Global Proteomics Market, by End-User Industry, 2019-2027
Summary Figure B : Global Proteomics Market, by Platform, 2022-2027
Figure 1 : Proteomics Biochip and Array Formats
Figure 2 : Chromatography Proteomics Workflow
Figure 3 : Agilent: Annual Revenue, Life Sciences and Applied Markets Segment, 2019-2021
Figure 4 : Agilent: Revenue Share, by Region, Life Sciences and Applied Markets Segment, 2021
Figure 5 : Danaher Corp.: Revenue Share, by Segment, 2020
Figure 6 : Danaher: Life Sciences Segment, Annual Revenue, 2019-2021
Figure 7 : Danaher: Life Sciences Segment Revenue Share, by Region, 2021
Figure 8 : General Electric Co.: Revenue Share, by Complementary Segment, 2020
Figure 9 : General Electric Co.: Revenue Share, by Region/Country, 2020
Figure 10 : GE Healthcare: Revenue Share, by Region, 2019
Figure 11 : GE Healthcare: Revenue Share, by Segment, 2019
Figure 12 : GlaxoSmithKline PLC: Net Revenue, 2016-2021
Figure 13 : GlaxoSmithKline PLC: Revenue Share, by Business Segment, 2021
Figure 14 : GlaxoSmithKline PLC: Revenue Share, by Region, 2021
Figure 15 : Merck KGaA: Revenue Share, by Complementary Segment, 2020
Figure 16 : Merck KGaA: Annual Revenue, 2017-2020
Figure 17 : Merck KGaA: Revenue Share, by Region, 2020
Figure 18 : Merck KGaA: Revenue Share, by Investment, 2020
Figure 19 : Merck KGaA: Revenue Share, by Region, 2020
Figure 20 : PerkinElmer Inc.: Annual Revenue, 2019-2021
Figure 21 : PerkinElmer Inc.: Revenue Share, by Region, 2021
Figure 22 : Qiagen: Annual Revenue, 2019-2021
Figure 23 : Qiagen: Revenue Share, by Product Groups, 2021
Figure 24 : Qiagen: Revenue Share, by Region, 2021
Figure 25 : Roche: Revenue Share, by Segment, 2021
Figure 26 : Roche: Total Sales Share, by Product Segment, 2020
Figure 27 : Roche: Annual Revenue, 2019-2021
Figure 28 : Roche Core Laboratory Diagnostics Segment: Annual Revenue, 2019-2021
Figure 29 : Roche: Oncology Annual Revenue, 2018-2020
Figure 30 : Sanofi: Net Sales Share, by Business Segment, 2021
Figure 31 : Sanofi: Net Sales Share, by Region, 2021
Figure 32 : Sanofi Oncology Pharmaceuticals: Annual Revenue, 2018-2020
Figure 33 : Thermo Fisher Scientific Inc.: Revenue Share, by Segment, 2020
Figure 34 : Thermo Fisher Scientific: Annual Revenue, 2019-2021
Figure 35 : Thermo Fisher Scientific: Revenue Share, by Region, 2021
Figure 36 : Waters Corp.: Annual Revenue, 2019-2021
Figure 37 : Waters Corp.: Revenue Share, by Region, 2021

Product Code: BIO034F

Highlights:

The global proteomics market should reach $55.1 billion by 2027 from $27.1 billion in 2022 at a compound annual growth rate (CAGR) of 15.3% for the forecast period of 2022 to 2027.

Drug discovery and development segment of the global proteomics market is expected to grow from $14.0 billion in 2022 to $26.1 billion in 2027 at a CAGR of 13.2% for the forecast period of 2022 to 2027.

Diagnostics segment of the global proteomics market is expected to grow from $7.4 billion in 2022 to $17.4 billion in 2027 at a CAGR of 18.5% for the forecast period of 2022 to 2027.

Report Scope:

The study's scope covers MS instruments, consumables, workflow products, planar arrays, bead arrays, and LOACs. It also covers the research, drug discovery and development, diagnostics, and applied end-user market segments. The main geographical markets-North America, Europe, Asia-Pacific, and Rest of the World (ROW)-are included.

The MS market is covered by instrument type, MS consumables, and product type and end-user markets. The biochip market is covered by biochip type and the end-user market for each type. The diagnostics market is covered in some detail, including by major platform (i.e., MS, biochips), by disease type and for cancer by indication. This report provides the current market sizes for these segments, as well as their forecasted growth to 2027.

Technology status and forces driving the market are discussed and analyzed. Factors that influence each market are also highlighted, including growth-driving forces, industry alliances and acquisitions, applications in diagnostics and drug discovery, customer needs, and competitive trends.

Key industry acquisitions and strategic alliances are given for the five-year period from 2021 through 2027.

This report examines the main patent trends within the industry and profiles proteomics companies.

Report Includes:

149 data tables and 97 additional tables
An up-to-date overview of the global markets for proteomics and related technologies
Analyses of the global market trends, with historic market revenue data from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
Highlights of the upcoming market potential for the global proteomics industry, growth driving factors, and areas of focus to forecast this market into various segments and sub-segments
Estimation of the actual market size and market forecast for proteomics in value (USD millions) terms, and their corresponding market share analysis by platform technology, end-user application, and region
In-depth information (facts and figures) concerning major market dynamics (DROs), technology advancements, new products and applications in proteomics, and COVID-19 impact on the market for proteomics
Insight into recent industry structure for proteomics technologies, competitive aspects of each product segments, major growth strategies, and company value share analysis based on their segmental revenues
Updated information on key mergers and acquisition deals, agreements, partnerships, collaborations and product launches within the global proteomics industry
Profile descriptions of the leading proteomics manufacturers, including Agilent, Danaher Corp., GlaxoSmithKline PLC, PerkinElmer Inc., Qiagen GmbH, and Sanofi.

Chapter 1 Introduction

1.1 Study Goals and Objectives
1.2 Reasons for Doing the Study
1.3 What's New in This Update?
1.4 Scope of Report
1.5 Intended Audience
1.6 Methodology
1.7 Information Sources
1.8 Analyst's Credentials
1.9 BCC Custom Research
1.10 Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Overview

3.1 Proteomic Technologies
3.2 Scope of Report
3.3 Proteomics Market
3.4 Driving Forces for Proteomics Industry Growth
- 3.4.1 Drivers
- 3.4.2 Restraints
- 3.4.3 Opportunities
- 3.4.4 Challenge
- 3.4.5 Proteomics Industry

Chapter 4 COVID 19 Impact on Proteomics Market

4.1 Overview
4.2 COVID-19 Crisis
4.3 Impact on Market
4.4 Current Outlook
- 4.4.1 Implications on Cancer Diagnosis
- 4.4.2 Key Reasons for Impact of COVID-19

Chapter 5 Proteomics Technologies

5.1 Introduction
5.2 MS-Based Proteomics Technologies
- 5.2.1 Sample Preparation Assays
- 5.2.2 Tagging/Affinity Methods
- 5.2.3 Utility of Proteomics to Identify Biomarkers
- 5.2.4 MS Instruments and Consumables
5.3 Biochip-Based Proteomics Technologies
- 5.3.1 Multiplex Proteomics Systems
- 5.3.2 Proteogenomics
- 5.3.3 Recent Advances in Proteomics Technologies

Chapter 6 Proteomics Applications in Drug Discovery and Development

6.1 Target Discovery
6.2 Lead Identification
6.3 Lead Optimization
6.4 Preclinical Studies

Chapter 7 Proteomics Scientific Initiatives

Chapter 8 Clinical Proteomics Applications

8.1 Applications in Cancer
- 8.1.1 Overview
- 8.1.2 Bladder Cancer
- 8.1.3 Breast Cancer
- 8.1.4 Colorectal Cancer
- 8.1.5 Gastric Cancer
- 8.1.6 Kidney Cancer
- 8.1.7 Lung Cancer
- 8.1.8 Lymphomas
- 8.1.9 Ovarian Cancer
- 8.1.10 Pan-Cancer
- 8.1.11 Prostate Cancer
- 8.1.12 Thyroid Cancer
- 8.1.13 Other Cancers
8.2 Infectious Diseases
8.3 Diabetes
8.4 Neurological Disorders
- 8.4.1 Alzheimer's Disease
- 8.4.2 Schizophrenia
8.5 Immune Diseases
- 8.5.1 HLA Typing
- 8.5.2 Autoimmune Disease
8.6 Cardiovascular Disease
8.7 Preeclampsia

Chapter 9 Proteomics Industry

9.1 Industry Acquisitions
9.2 Industry Strategic Alliances
9.3 Mass Spectrometry Industry
9.4 Chromatography Industry
9.5 Proteomics-Based Drug Discovery and Development Industry
9.6 Proteomics Biochip Industries
- 9.6.1 Peptide Microarray Industry
- 9.6.2 High-Density Protein Array Industry
9.7 Antibody Microarray Industry
9.8 China's Biochip Industry
9.9 Lab-on-a-Chip Proteomics Industry
9.10 Chemical Proteomics Industry
9.11 Antibody Reagent Industry
9.12 Multiplex Protein Diagnostics Industry
9.13 Dried Blood Spotting Proteomics Industry
9.14 Single Cell Proteomics Industry

Chapter 10 Proteomics Markets

10.1 Driving Forces of Proteomics Industry Growth
10.2 Global Proteomics Markets
10.3 Market Summary
10.4 Research Market
10.5 Drug Discovery and Development Market
10.6 Proteomics Diagnostic Market
10.7 Mass Spectrometry-Based Proteomics Market
10.8 Biochip-Based Proteomics Market

Chapter 11 Proteomics Market by Geographic Segmentation

11.1 North America
- 11.1.1 United States
- 11.1.1 Canada
11.2 Europe
- 11.2.1 Impact of Brexit
- 11.2.2 United Kingdom
- 11.2.3 Germany
- 11.2.4 France
- 11.2.5 Italy
- 11.2.6 Spain
- 11.2.7 Rest of Europe
11.3 Asia-Pacific
- 11.3.1 China
- 11.3.2 Japan
- 11.3.3 India
- 11.3.4 South Korea
- 11.3.5 Australia
- 11.3.6 Rest of Asia-Pacific
11.4 Rest of the World (RoW)

Chapter 12 Proteomics Patents

12.1 U.S. Proteomics Patents
12.2 Protein Array Patents
- 12.2.1 Lab-on-a-Chip Patents
- 12.2.2 Mass Spectrometry Patents

Chapter 13 Competitive Landscape

13.1 Genomics and Proteomic Tools/Technologies
- 13.1.1 Sequencing Technologies
- 13.1.2 PCR Technology
- 13.1.3 Nucleic Acid Purification and Separation
- 13.1.4 Nucleic Acid Separation Technologies

Chapter 14 Company Profiles

ABCODIA LTD.
ACTIVX BIOSCIENCES INC.
ADVANCED PROTEOME THERAPEUTICS INC.
AGILENT TECHNOLOGIES INC.
APPLIED PROTEOMICS
ARRAYIT CORP.
ASTUTE MEDICAL INC.
AVACTA LIFE SCIENCES LTD.
AYOXXA BIOSYSTEMS GMBH
BECTON, DICKINSON AND CO.
BIOCARTIS NV
BIODESIX INC.
BIOGNOSYS AG
BIOMERIEUX SA
BIO-RAD LABORATORIES INC.
BIO-TECHNE INC.
BRUKER CORP.
CAMBRIDGE PROTEIN ARRAYS LTD.
CHARLES RIVER LABORATORIES INTERNATIONAL INC.
CRYSTALGENOMICS INC.
DANAHER CORP.
EPICYPHER INC.
EVOTEC AG
GENERAL ELECTRIC CO.
GLAXOSMITHKLINE PLC
GL SCIENCES INC.
ILLUMINA INC.
IMMUNOVIA AB
IMTAKT CORP.
INTEGRATED DIAGNOSTICS HOLDING
INDI MOLECULAR
LABCYTE INC.
LIMINAL BIOSCIENCES INC.
MERCK & CO. INC.
MERCK KGAA
MRM PROTEOMICS INC.
MYCARTIS
MYRIAD GENETICS INC.
NEWOMICS INC.
NIRMIDAS BIOTECH INC.
OLINK BIOSCIENCE
OPKO HEALTH INC.
PERKINELMER INC.
PERSONALIZED CANCER THERAPY INC.
PFIZER INC.
PHENOMENEX INC.
PRESSURE BIOSCIENCES INC.
PROTAGEN AG
PROTEA BIOSCIENCES INC.
PROTEOCYTE DIAGNOSTICS INC.
PROTEOGENIX
PROTEOME SCIENCES PLC
PROTEOMICS INTERNATIONAL PTY LTD.
PYC THERAPEUTICS. (FORMERLY PHYLOGICA LTD.)
QIAGEN N.V.
QUANSYS BIOSCIENCES
QUANTERIX INC.
QUEST DIAGNOSTICS INC.
REPLIGEN CORP.
ROCHE (F. HOFFMANN-LA ROCHE LTD.)
SAMDI TECH INC.
SANOFI
SERA PROGNOSTICS
SHIMADZU CORP.
SHISEIDO COMPANY LTD.
SHOWA DENKO KK
SINGULEX INC.
SISCAPA ASSAY TECHNOLOGIES INC.
SOMALOGIC INC.
SPOTON CLINICAL DIAGNOSTICS LTD.
SQI DIAGNOSTICS
STANDARD BIOTOOLS INC. (FORMERLY FLUIDIGM)
SYNAGEVA BIOPHARMA (ACQUIRED BY ALEXION PHARMACEUTICALS INC.)
T2 BIOSYSTEMS
THERMO FISHER SCIENTIFIC INC.
THORNE DIAGNOSTICS INC.
TOSOH CORP.
TRAJAN SCIENTIFIC AND MEDICAL
UNIVERSAL BIOSENSORS LTD.
VG LIFE SCIENCES INC.
WATERS CORP.
XENCOR INC.
YMC CO. LTD.

プロテオミクス：各種技術と世界の市場

Proteomics: Technologies and Global Markets

目次

第1章イントロダクション

第2章サマリー・ハイライト

第3章概要

第4章 COVID-19がプロテオミクス市場に与える影響

第5章プロテオミクス技術

第6章創薬・開発におけるプロテオミクスの応用

第7章プロテオミクスの科学的イニシアチブ

第8章プロテオミクスの臨床用途

第9章プロテオミクス産業

第10章プロテオミクス市場

第11章プロテオミクス市場：地域別

第12章プロテオミクス特許

第13章競合情勢

第14章企業プロファイル

List of Tables

List of Figures

Highlights:

Report Scope:

Report Includes:

Table of Contents

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Overview

Chapter 4 COVID 19 Impact on Proteomics Market

Chapter 5 Proteomics Technologies

Chapter 6 Proteomics Applications in Drug Discovery and Development

Chapter 7 Proteomics Scientific Initiatives

Chapter 8 Clinical Proteomics Applications

Chapter 9 Proteomics Industry

Chapter 10 Proteomics Markets

Chapter 11 Proteomics Market by Geographic Segmentation

Chapter 12 Proteomics Patents

Chapter 13 Competitive Landscape

Chapter 14 Company Profiles

プロテオミクス：各種技術と世界の市場

Proteomics: Technologies and Global Markets

目次

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 概要

第4章 COVID-19がプロテオミクス市場に与える影響

第5章 プロテオミクス技術

第6章 創薬・開発におけるプロテオミクスの応用

第7章 プロテオミクスの科学的イニシアチブ

第8章 プロテオミクスの臨床用途

第9章 プロテオミクス産業

第10章 プロテオミクス市場

第11章 プロテオミクス市場：地域別

第12章 プロテオミクス特許

第13章 競合情勢

第14章 企業プロファイル

List of Tables

List of Figures

Highlights:

Report Scope:

Report Includes:

Table of Contents

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Overview

Chapter 4 COVID 19 Impact on Proteomics Market

Chapter 5 Proteomics Technologies

Chapter 6 Proteomics Applications in Drug Discovery and Development

Chapter 7 Proteomics Scientific Initiatives

Chapter 8 Clinical Proteomics Applications

Chapter 9 Proteomics Industry

Chapter 10 Proteomics Markets

Chapter 11 Proteomics Market by Geographic Segmentation

Chapter 12 Proteomics Patents

Chapter 13 Competitive Landscape

Chapter 14 Company Profiles

第1章イントロダクション

第2章サマリー・ハイライト

第3章概要

第5章プロテオミクス技術

第6章創薬・開発におけるプロテオミクスの応用

第7章プロテオミクスの科学的イニシアチブ

第8章プロテオミクスの臨床用途

第9章プロテオミクス産業

第10章プロテオミクス市場

第11章プロテオミクス市場：地域別

第12章プロテオミクス特許

第13章競合情勢

第14章企業プロファイル